Therapeutic | Infliximab |
Target | TNFA |
Heavy Chain | EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS |
Light Chain | DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK |
100% seqID Fv Structure | 5vh3%3AHL%3AAB%2F5vh4%3AHL%3AAB%2F4g3y%3AHL%2F6ugs%3AHL%3AAB%2F6ugv%3AHL%3AAB%2F6ugt%3AHL%3AAB%2F6ugu%3AHL%3AAB [Fvs: ] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 1997 |
INN Year Recommended | 1998 |
Companies Involved | Centocor%3BJanssen Biotech%3BMerck %26 Co%3BMitsubishi Tanabe Pharma Corporation%3BNational Jewish Medical and Research Center%3BXian-Janssen |
Conditions Approved | Ankylosing spondylitis%3BBehcet%27s syndrome%3BCrohn%27s disease%3BMucocutaneous lymph node syndrome%3BPlaque psoriasis%3BPsoriasis%3BPsoriatic arthritis%3BRheumatoid arthritis%3BUlcerative colitis |
Conditions Active | na |
Conditions Discontinued | Berylliosis%3BHepatitis C%3BPyoderma |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]